Hematopoietic Progenitor Cells and The Treatment of Malignant Diseases

1656 Words7 Pages
Introduction
The proper processing, storage, and selection of hematopoietic progenitor cell (HPC) products for transplantation is essential to maintaining the product’s viability, and reducing the likelihood of adverse recipient reactions. Hematopoietic progenitor cells are most commonly used to treat a variety of malignant hematological diseases. Some nonmalignant diseases may also be treated with HPC transplantation, but because of the high risk of fatal complications associated with the procedure, it is uncommon. Hematopoietic progenitor cells are collected from thoroughly screened donors using one of three different methods: bone marrow collection, peripheral blood apheresis, and umbilical cord blood collection. After collection, HPC products are sent to a cellular therapy laboratory for processing, storage, and dispensing. Laboratory personnel inspect every product that arrives and then perform a series of qualitative and quantitative tests on samples from each unit. The HPCs are processed according to their type and are then either transplanted fresh, or prepared for frozen storage. The freezing process requires the use of cryoprotectant chemicals and must be performed under specific conditions to avoid damaging the cells. Frozen HPCs must be thawed and tested to ensure viability before they are transplanted. The transplantation of HPCs is a risky procedure with the potential to cause a variety adverse reactions in transplant recipients, including graft-versus-host disease (GVHD), and ABO incompatibility reactions (Kennedy & Scrape, 2012).
Body of Paper
The processing and preparation of HPC products at the cellular therapy laboratory is essential to the transformation of donor cells into HPC products that are safe to t...

... middle of paper ...

...Works Cited

Kennedy, M. S., & Scrape, S. (2012). Cellular therapy. In D. M. Harmening (Ed.), Modern blood banking & transfusion practices (6th ed.) (pp. 391-402). Philadelphia, PA: F.A. Davis.
Lane, T. A., & McMannis, J. D. (2011). Hematopoietic progenitor cells collected by apheresis. In J. D. Roback (Ed.), Technical manual (17th ed.) (pp. 801-822). Bethesda, MD: AABB.
National Cancer Institute. (2014, April 8a). Allogenic HCT. Retrieved from http://www.cancer.gov/cancertopics/pdq/treatment/childHCT/HealthProfessional/page3
National Cancer Institute. (2014, April 8b). Complications after HCT. Retrieved from http://www.cancer.gov/cancertopics/pdq/treatment/childHCT/HealthProfessional/page4
Tormey, C. A. (2011). Transfusion support for hematopoietic stem cell transplant recipients. In J. D. Roback (Ed.), Technical manual (17th ed.) (pp. 687-705). Bethesda, MD: AABB.

More about Hematopoietic Progenitor Cells and The Treatment of Malignant Diseases

Open Document